Electrovac (EVAC) Q1 2027 earnings summary

Executive summary

• Revenue increased by 12.0% year-over-year to EUR 31.5 million in Q1 2026/2027, with EBIT up 11.0% to EUR 3.2 million.

• Adjusted EBIT, excluding one-time IPO costs, nearly doubled to EUR 5.4 million, reflecting improved operating performance.

• Strong order intake in Aerospace & Defense and Industrials segments, with a book-to-bill ratio of 2.30.

• Successful IPO in April 2026 generated EUR 29.95 million in gross proceeds, strengthening equity and liquidity.

Financial highlights

• Gross profit rose to EUR 7.9 million from EUR 5.7 million year-over-year.

• Operating cash flow (adjusted for IPO costs) increased to EUR 1.5 million from EUR 0.6 million.

• Cash and cash equivalents surged to EUR 25.8 million as of June 30, 2026, from EUR 2.1 million at March 31, 2026.

• Equity ratio improved to 68.2% from 55.1% sequentially.

• Earnings per share (basic/diluted) was EUR 0.11, compared to EUR 0.12 in the prior year.

Outlook and guidance

• Full-year 2026/2027 revenue forecast confirmed at EUR 120–130 million, with EBIT expected between EUR 11.0–12.0 million.

• Adjusted EBIT guidance (excluding IPO costs) is EUR 13.0–14.0 million.